news

WHO guidance aims to strengthen clinical trial ecosystem

6
SHARES

The new recommendations are applicable to clinical trials in countries of all income levels and seek to make trials more effective and supportive for a diverse range of participants.

World Health Organization (WHO) clinical trials

New global guidance on best practices to improve clinical trials has been released by the World Health Organization (WHO).

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Fundamentally, the document offers approaches aimed at enhancing the design, conduct and oversight of clinical trials, to strengthen country-led R&D ecosystems.

The guidance is relevant to clinical trials including pharmaceutical medicines, vaccines, behavioural and psychological interventions, preventive care, as well as digital and public health approaches and traditional or herbal measures.

What clinical trial recommendations are included?

For the first time, recommendations are offered for organisations such as national health authorities, regulators and funders on ways to enable clinical trials to generate evidence on health interventions, according to WHO. Key challenges including poor trial design and limited diversity of participants are highlighted.

for the first time, recommendations are offered for organisation such as national health authorities, regulators and funders on ways to enable clinical trials to generate evidence on health interventions”

One of the key aspects of the guidance is ensuring trials are patient-centric, with participant engagement being at the centre of the organisation of clinical trials. For example, ensuring research planning and delivery addresses the needs of the public, WHO noted.

The agency explained that practical considerations for setting up trials to include pregnant and lactating women is part of the new guidance. They stated that a safety assessment should be a primary priority, eg, by “reviewing comparable interventions or expediting pre-clinical studies for these groups. Appropriate procedures for consent and assent are key, particularly for children”.

Furthermore, the guidance seeks improve national R&D via “sustainable financing, to support better decision-making, accelerate access to health innovation and build more robust and effective national and global health research environments”.

“Strengthening country-led research and development and embedding clinical trials in routine clinical and public health services will ensure faster and more equitable access to safe and effective interventions,” commented Dr Jeremy Farrar, WHO’s Chief Scientist. “This new guidance aims to improve the diversity of trial participants to ensure research benefits the broadest range of people possible, decisively moving away from a one-size-fits-all approach.”

Share via
Share via